



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

| APPLICATION NO.         | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-------------------------|-------------|----------------------|---------------------|------------------|
| 10/728,339              | 12/04/2003  | Marc Nazare          | DEAV2002/0085 US NP | 8596             |
| 5487                    | 7590        | 02/20/2007           | EXAMINER            |                  |
| ROSS J. OEHLER          |             |                      | SOLOLA, TAOFIQ A    |                  |
| SANOFI-AVENTIS U.S. LLC |             |                      | ART UNIT            | PAPER NUMBER     |
| 1041 ROUTE 202-206      |             |                      | 1625                |                  |
| MAIL CODE: D303A        |             |                      |                     |                  |
| BRIDGEWATER, NJ 08807   |             |                      |                     |                  |
| NOTIFICATION DATE       |             | DELIVERY MODE        |                     |                  |
| 02/20/2007              |             | ELECTRONIC           |                     |                  |

Please find below and/or attached an Office communication concerning this application or proceeding.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPatent.E-Filing@sanofi-aventis.com  
andrea.ryan@sanofi-aventis.com

**Advisory Action  
Before the Filing of an Appeal Brief**

|                              |                  |                               |
|------------------------------|------------------|-------------------------------|
| Application No.              | 10/728,339       | Applicant(s)<br>NAZARE ET AL. |
| Examiner<br>Taofiq A. Solola | Art Unit<br>1625 |                               |

**--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

THE REPLY FILED 04 January 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1.  The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

a)  The period for reply expires \_\_\_\_\_ months from the mailing date of the final rejection.

b)  The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**NOTICE OF APPEAL**

2.  The Notice of Appeal was filed on \_\_\_\_\_. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

**AMENDMENTS**

3.  The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because
- (a)  They raise new issues that would require further consideration and/or search (see NOTE below);
  - (b)  They raise the issue of new matter (see NOTE below);
  - (c)  They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
  - (d)  They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: \_\_\_\_\_. (See 37 CFR 1.116 and 41.33(a)).

4.  The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5.  Applicant's reply has overcome the following rejection(s): None.

6.  Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7.  For purposes of appeal, the proposed amendment(s): a)  will not be entered, or b)  will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: \_\_\_\_\_.

Claim(s) objected to: 12 and 14.

Claim(s) rejected: 1,13 and 15-18.

Claim(s) withdrawn from consideration: \_\_\_\_\_.

**AFFIDAVIT OR OTHER EVIDENCE**

8.  The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9.  The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10.  The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

**REQUEST FOR RECONSIDERATION/OTHER**

11.  The request for reconsideration has been considered but does NOT place the application in condition for allowance because: see attached.


12.  Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). \_\_\_\_\_

13.  Other: \_\_\_\_\_.

Taofiq A. Solola  
Primary Examiner  
Art Unit: 1625

***Rejoinder***

In a recent telephone interview with the Examiner, applicant's representative requests rejoinder of non-elected invention, claims 13, 15-17. Since the instant application is After Final, such rejoinder is deemed an amendment after Final. Applicant's representative was advised that the claims are not allowable and therefore, the Examiner would issue Advisory Action.



Claim 1: formula and the phraseology

provided that where R<sup>0</sup> is a monocyclic or bicyclic 6- to 14-membered aryl, then R<sup>8</sup> is at least one halogen, -C(O)-NH<sub>2</sub> or -O-(C<sub>1</sub>-C<sub>8</sub>)-alkyl residue;

render the claim indefinite and must be deleted.

Claims 13, 18: Not within the scope of claim 1. Substitution of imidazole ring is other than in claim 1. The substituents in claim 13 have definitions that are not in claim 1.

Claim 15-16: Are not drawn to practical utilities. It is not clear what applicant means by "influence blood coagulation [or] fibrinolysis". One must read the specification into the claims contrary to several US courts' decisions. Such reading of the specification renders the claims duplicates of 17.

Claim 17: While anticoagulant may be used in the course of treating the listed diseases, the anticoagulant does not treat several of the diseases, such as, MI, viral infection, etc. The claim should be drawn to a method of using the compounds as antithrombic agents. No need to list the diseases where thrombosis may occur.

***Telephone Inquiry***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, PhD. JD., whose telephone number is (571) 272-0709.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Thomas McKenzie, can be reached on (571) 272-0670. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.



**TAOIQ SOLOLA**  
**PRIMARY EXAMINER**

Group 1625

February 5, 2007